▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1361 by analyst upside · 2026-11-13
PHVS
Pharvaris N.V.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+71.0%
implied upside to consensus target
Current Price $33.83
Consensus Target $57.85
Bull Target $79.05
Bear Target $40.52
Analysts Covering 14
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
11
Hold
0
Sell
0
52-Week Low $22.77
52-Week High $43.25
YTD Return +27.8%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.06
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $22.77
52-Week High $43.25
Current Price $33.83
Bear Target $40.52
Bull Target $79.05
● Now $33.83 ● Target $57.85
TRADING DATA
Avg Volume 798K
YTD Return +27.8%
Analyst Count 14
Consensus Buy
Upside to Target +71.0%
Last Updated 2026-11-13

ANALYST SUMMARY

Pharvaris N.V. (PHVS) is currently trading at $33.83 with a Wall Street consensus price target of $57.85, implying potential upside of 71.0% over the next 12 months. 14 analysts currently cover PHVS, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $79.05, while the most cautious has a target of $40.52.

PHVS operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 27.8% year-to-date and is currently trading near the upper end of its 52-week range of $22.77 – $43.25.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

PBH +46.1%
Prestige Consumer Healthcare Inc.
$2B · P/E 14.0x · Buy
HRMY +42.3%
Harmony Biosciences Holdings, Inc.
$2B · P/E 11.2x · Buy
VCYT +81.1%
Veracyte, Inc.
$2B · P/E 16.0x · Buy
AVAH +23.4%
Aveanna Healthcare Holdings Inc.
$3B · P/E 9.7x · Buy
ACAD +68.3%
Acadia Pharmaceuticals Inc.
$3B · P/E 8.6x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for PHVS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

B of A Securities ↑ Upgrade
Neutral → Buy 2026-10-23 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-09-10 62% win rate (8 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-09-09 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-09-09 29% win rate (7 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2026-09-09 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-09-09 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-09-09 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-09-09 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
55
out of 100
Coverage depth
21/30
Consensus clarity
7/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →